 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 4 | 4 | 8 | | 1999 | 4 | 3 | 7 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 1 | 6 | | 2002 | 4 | 1 | 5 | | 2003 | 2 | 2 | 4 | | 2004 | 9 | 1 | 10 | | 2005 | 8 | 4 | 12 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 2 | 7 | | 2008 | 9 | 2 | 11 | | 2009 | 10 | 3 | 13 | | 2010 | 10 | 2 | 12 | | 2011 | 8 | 8 | 16 | | 2012 | 17 | 2 | 19 | | 2013 | 14 | 4 | 18 | | 2014 | 23 | 6 | 29 | | 2015 | 15 | 6 | 21 | | 2016 | 33 | 9 | 42 | | 2017 | 30 | 7 | 37 | | 2018 | 28 | 6 | 34 | | 2019 | 25 | 6 | 31 | | 2020 | 31 | 6 | 37 | | 2021 | 41 | 5 | 46 | | 2022 | 41 | 0 | 41 | | 2023 | 33 | 2 | 35 | | 2024 | 21 | 9 | 30 | | 2025 | 36 | 4 | 40 | | 2026 | 23 | 3 | 26 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Irie WC, Corneli A, Perry B, Kelsey C, Bickham J, Davenport T, Naresh A, Holman S, Clement M. Start the Conversation: Development of a Training Program to Build OB/GYN Resident Capacity for PrEP Prescribing in Routine Care. J Int Assoc Provid AIDS Care. 2026 Jan-Dec; 25:23259582261488339.
-
Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang L, von Kleist M, Hendrix CW, Momper JD, Bies R, Scott RK. Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum. J Clin Pharmacol. 2026 Sep; 66(9):e70278.
-
Tagliaferri Rael C, Das D, Giguere R, Porter J, Bryndza Tfaily E, Tuswa Haynes C, Ho T, McKenna S, Lopez-Ríos J, Lentz C, Dolezal C, Stonbraker S, Hendrix C, D'Aquila RT, Hope TJ. Provider Preferences on Existing and Potential Future Biomedical HIV Prevention Products: A Qualitative Study in the United States, Thailand, and South Africa. AIDS Res Hum Retroviruses. 2026 Oct-Nov; 42(10-11):307-317.
-
Haw NJL, Hogan B, Humes E, Coburn SB, Zheng C, Cheng Y, Zhang Y, Gebo KA, Lam JO, Karris MY, Zalla LC, Horberg MA, Napravnik S, Gill MJ, Althoff KN, Lesko CR. New to cohort, not new to care: leveraging historical data in HIV clinical cohorts in the United States. Am J Epidemiol. 2026 Aug 05; 195(8):2287-2296.
-
Dunbar A, Rakhmanina N, Unternaher J, Anderson PL, Brooks KM. Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities. J Clin Pharmacol. 2026 Aug; 66(8):e70249.
-
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026 Jul 23; 83(1):e81-e89.
-
Puccinelli M, Mayer KH, Esquivel-Mendoza JA, Porras A, Psaros C, Krakower D, Doblecki-Lewis S, Anderson PL, Mimiaga MJ, Safren SA. Life-steps for PrEP nurse-delivered adherence intervention: Protocol for a multisite randomized clinical trial. Contemp Clin Trials. 2026 Sep; 168:108405.
-
Ridolfi F, Amorim G, Haas DW, Arriaga M, Staats C, Cordeiro-Santos M, Kritski AL, Figueiredo MC, Andrade BB, Sterling TR, Rolla VC, Benjamin A, Sant'Anna FM, Oliveira JG, Marin J, Rezende A, Carvalho AC, Rocha M, Nogueira B, Brito A, Spener R, Turner M. Determinants of HIV-1 virologic suppression in HIV-associated tuberculosis in Brazil. Mem Inst Oswaldo Cruz. 2026; 121:e250090.
-
Torres TS, Silva MST, Hoagland B, Marins LMS, Coutinho C, Jalil EM, Leite P, Cunha M, Moreira R, Leite IC, Konda K, Guanira J, Benedetti M, Pimenta C, Vega-Ramirez H, Cardoso SW, Caceres CF, Anderson PL, Grinsztejn B, Veloso VG. Using Tenofovir Diphosphate Levels to Evaluate Factors Associated With PrEP Non-Adherence and Performance of Indirect Adherence Measures in Latin America: A Prospective, Single-Arm, Open-Label, Multicentre Implementation Study (ImPrEP). J Int AIDS Soc. 2026 Jul; 29 Suppl 3:e70154.
-
Moeser MJ, Council OD, Long N, Kincer L, Dennis AM, Eron J, Wohl D, Farel CE, Dittmer DP, Pluta L, Nelson J, Mohammadi A, Etemad B, Li JZ, McGann H, Smit E, Clement M, Yau T, Menezes P, Bowman NM, Zhou S, Joseph SB. A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage. J Infect Dis. 2026 Jun 16; 233(6):1005-1014.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|